Detalles de la búsqueda
1.
Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
BMC Infect Dis
; 15: 409, 2015 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26437712
2.
Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.
BMC Infect Dis
; 13: 116, 2013 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23510357
3.
Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Hum Vaccin
; 6(8): 640-51, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20697200
4.
Safety and immunogenicity of a tetravalent polysaccharide vaccine against meningococcal disease.
J Formos Med Assoc
; 108(7): 539-47, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19586827
5.
Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus.
Hum Vaccin Immunother
; 15(12): 2980-2992, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31149870
6.
Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
Pediatr Infect Dis J
; 27(7): 579-88, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18536619
7.
Primary vaccination with a new heptavalent DTPw-HBV/Hib-Neisseria meningitidis serogroups A and C combined vaccine is well tolerated.
Int J Infect Dis
; 12(1): 88-97, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17716936
8.
A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
Pediatr Infect Dis J
; 26(11): 1057-9, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17984816
9.
Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae Type b and Neisseria meningitidis Serogroup C-tetanus toxoid conjugate vaccine coadministered with a Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months.
Pediatr Infect Dis J
; 26(1): 1-7, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17195697
10.
Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study.
Hum Vaccin Immunother
; 11(3): 632-41, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25483694
11.
Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.
Hum Vaccin Immunother
; 11(3): 620-31, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25715157
12.
Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.
Clin Vaccine Immunol
; 21(1): 56-65, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24173029
13.
Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.
Clin Vaccine Immunol
; 21(3): 302-11, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24391139
14.
A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Pediatr Infect Dis J
; 32(5): 521-9, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23190785
15.
Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.
Hum Vaccin Immunother
; 8(7): 866-72, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22485049
16.
The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
Int J Infect Dis
; 16(8): e608-15, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22704725
17.
Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
Hum Vaccin Immunother
; 8(12): 1892-903, 2012 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23032159
18.
A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.
Hum Vaccin Immunother
; 8(12): 1882-91, 2012 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23032168
19.
Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Pediatr Infect Dis J
; 31(10): 1074-7, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22828645
20.
Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine.
Pediatr Infect Dis J
; 30(3): 190-6, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20948453